Amber Witteman Ebenroth B.V. EPIWatch

Amber Witteman is Founding – Managing Director at EPIWatch, part of Ebenroth B.V. EPIWatch (Combination Product) is the first wearable Auto Injector for intramuscular drug delivery that is also suitable for subcutaneous applications and markets. EPIWatch is a next generation wearable auto injector incorporated in a smart watch, that is connected to the IoT. Bio Sensor Health Care Technology (AI) can be incorporated within the EPIWatch housing in a later stage to generate patient centric healthcare profiles for improvement of future treatment and R&D. Amber has been in the industry since 2009 and her focus is on patient comfort, need and requirements. Amber is considered an Experience Expert and an Innovation Leader.

Amber is responsible for inventing, filling, and developing the concept patent, the mechanical patent and filling for the latest patent that contains a material that allows drug temperature control within the PFS, ampoules, vials, cartridges, etc. up to 50 degrees Celsius in the sun, keeping the drug cool while maintaining glass and polymer transparency. The mechanical patent contains a novel drug delivery system where the needle is integrated within the primary container called the needle in plunger (NIP) a novel drug delivery system making the PFS an integrated unit, extremely compact and easier to replace, taking away a significant deal of needle fear.

Amber also engineered the Oval shaped container for on body worn drug delivery devices, making the primary container as flat as possible. Amber her expertise is tackling critical aspects and innovating key drivers with a focus on low -and zero depth space, minimum waist, patient comfort -and safety.